Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
暂无分享,去创建一个
K. Chergui | F. Gonon | H. Schoemaker | C. Carter | Y. Claustre | D. Fage | L. Rouquier | O. Curet | A. Oblin | J. Bénavidès | B. Scatton | J. Benavides
[1] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[2] S. Snyder,et al. Strychnine binding associated with glycine receptors of the central nervous system. , 1973, Proceedings of the National Academy of Sciences of the United States of America.
[3] K. Catt,et al. Properties of angiotensin II receptors in the bovine and rat adrenal cortex. , 1974, The Journal of biological chemistry.
[4] S. Snyder,et al. The glycine synaptic receptor: evidence that strychnine binding is associated with the ionic conductance mechanism. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[5] S. Snyder,et al. Muscarinic cholinergic binding in rat brain. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[6] A. Young,et al. Gamma-aminobutyric acid binding to receptor sites in the rat central nervous system. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[7] J. Contrera,et al. BINDING OF [3H]KAINIC ACID, AN ANALOGUE OF l‐GLUTAMATE, TO BRAIN MEMBRANES , 1976, Journal of neurochemistry.
[8] J. Korf,et al. Regional effects of neuroleptics on dopamine metabolism and dopamine-sensitive adenylate cyclase activity. , 1977, European journal of pharmacology.
[9] V. Klimek,et al. The influence of antiserotonergic agents on the action of dopaminergic drugs. , 1977, Polish journal of pharmacology and pharmacy.
[10] J. Leysen,et al. Spiperone: a ligand of choice for neuroleptic receptors. 2. Regional distribution and in vivo displacement of neuroleptic drugs. , 1978, Biochemical pharmacology.
[11] J. Leysen,et al. Spiperone: a ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding. , 1978, Biochemical pharmacology.
[12] G. Di Chiara,et al. Self-inhibitory dopamine receptors: their role in the biochemical and behavioral effects of low doses of apomorphine. , 1978, Advances in biochemical psychopharmacology.
[13] M. Briley,et al. Two binding sites for 3H-spiroperidol on rat striatal membranes. , 1978, European journal of pharmacology.
[14] B. Costall,et al. Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity. , 1978, European journal of pharmacology.
[15] S. Snyder,et al. Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramine. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[16] C. Carter,et al. Behavioural and biochemical effects of dopamine and noradrenaline depletion within the medial prefrontal cortex of the rat , 1980, Brain Research.
[17] E. Mogilnicka,et al. Rapid-eye-movement sleep deprivation decreases the density of 3H-dihydroalprenolol and 3H-imipramine binding sites in the rat cerebral cortex. , 1980, European journal of pharmacology.
[18] M. H. Aprison,et al. Determination of the Equilibrium Dissociation Constants and Number of Glycine Binding Sites in Several Areas of the Rat Central Nervous System, Using a Sodium‐Independent System , 1981, Journal of neurochemistry.
[19] C. Carter,et al. The role of 5-hydroxytryptamine in dopamine-dependent stereotyped behaviour , 1981, Neuropharmacology.
[20] B. Scatton,et al. Determination of 5-hydroxytryptophan, serotonin and 5-hydroxyindoleacetic acid in rat and human brain and biological fluids by reversed-phase high-performance liquid chromatography with electrochemical detection. , 1981, Journal of chromatography.
[21] N. Bowery,et al. 3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABAB sites in rat brain , 1981, Nature.
[22] S. Z. Langer,et al. Duct ligation decreases [3H]clonidine binding in rat submaxillary glands. , 1982, European journal of pharmacology.
[23] P. Krogsgaard‐Larsen,et al. The Binding of [3H]AMPA, a Structural Analogue of Glutamic Acid, to Rat Brain Membranes , 1982, Journal of neurochemistry.
[24] M. Briley,et al. High-affinity [3H]desipramine binding in the peripheral and central nervous system: a specific site associated with the neuronal uptake of noradrenaline. , 1982, European journal of pharmacology.
[25] J. Vetulani,et al. Facilitation by α-adrenolytics of apomorphine gnawing behavior: Depression of threshold apomorphine concentration in the striatum of the rat , 1983, Pharmacology Biochemistry and Behavior.
[26] H. Schoemaker,et al. Specific high-affinity binding sites for [3H]Ro 5-4864 in rat brain and kidney. , 1983, The Journal of pharmacology and experimental therapeutics.
[27] G. Paxinos,et al. The Rat Brain in Stereotaxic Coordinates , 1983 .
[28] A. Barnett,et al. Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum. , 1984, Life sciences.
[29] J. Palacios,et al. The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. , 1984, European journal of pharmacology.
[30] H. Schoemaker,et al. 5HT-receptor antagonist properties of SCH 23390 in vascular smooth muscle and brain. , 1984, European journal of pharmacology.
[31] D. Clark,et al. Novel dopamine receptor agonists and antagonists with preferential action on autoreceptors. , 1985, Journal of medicinal chemistry.
[32] S O Ogren,et al. Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. , 1985, Biochemical pharmacology.
[33] L. Cubeddu,et al. Evidence for autoreceptor modulation of endogenous dopamine release from rabbit caudate nucleus in vitro. , 1985, The Journal of pharmacology and experimental therapeutics.
[34] Y. Claustre,et al. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors. , 1985, The Journal of pharmacology and experimental therapeutics.
[35] G. Lu,et al. Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. , 1986, Molecular pharmacology.
[36] H. Schoemaker,et al. [3H]8-OH-DPAT labels the serotonin transporter in the rat striatum. , 1986, European journal of pharmacology.
[37] P. Hartig,et al. Solubilization and characterization of the serotonin 5-HT1c site from pig choroid plexus. , 1986, Molecular pharmacology.
[38] J. Leysen,et al. [3H]Batrachotoxinin A 20-alpha-benzoate binding to sodium channels in rat brain: characterization and pharmacological significance. , 1986, European journal of pharmacology.
[39] S. Peroutka,et al. Pharmacological Differentiation and Characterization of 5‐HT1A, 5‐HT1B, and 5‐HT1C Binding Sites in Rat Frontal Cortex , 1986, Journal of neurochemistry.
[40] K. Fujimori,et al. Determination of Acetylcholine and Choline in Rat Brain Tissue by Liquid Chromatography/Electrochemistry Using an Immobilized Enzyme Post Column Reactor , 1986 .
[41] S. Paul,et al. Characterization of Sodium‐Dependent [3H]GBR‐12935 Binding in Brain: A Radioligand for Selective Labelling of the Dopamine Transport Complex , 1986, Journal of neurochemistry.
[42] R. Miller,et al. 3H-labeled MK-801 binding to the excitatory amino acid receptor complex from rat brain is enhanced by glycine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[43] S. Peroutka,et al. Characterization of a novel 3H-5-hydroxytryptamine binding site subtype in bovine brain membranes , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[44] J. Leysen,et al. Comparison of the In‐vitro Receptor Selectivity of Substituted Benzamide Drugs for Brain Neurotransmitter Receptors , 1988, The Journal of pharmacy and pharmacology.
[45] E. Wong,et al. [3H]MK‐801 Labels a Site on the N‐Methyl‐D‐Aspartate Receptor Channel Complex in Rat Brain Membranes , 1988, Journal of neurochemistry.
[46] G. Di Chiara,et al. Effects of locally applied D-1 and D-2 receptor agonists and antagonists studied with brain dialysis. , 1988, European journal of pharmacology.
[47] J. Drejer,et al. Chaotropic Ions Affect the Conformation of Quisqualate Receptors in Rat Cortical Membranes , 1988, Journal of neurochemistry.
[48] R. Struble,et al. Serotonin 5‐HT1D Receptors in Human Prefrontal Cortex and Caudate: Interaction with a GTP Binding Protein , 1988, Journal of neurochemistry.
[49] H. Schoemaker,et al. Effects of Ca++ on [3H]diltiazem binding and its allosteric interaction with dihydropyridine calcium channel binding sites in the rat cortex. , 1989, The Journal of pharmacology and experimental therapeutics.
[50] H. Meltzer,et al. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.
[51] A. Delcker,et al. Amisulpride Versus Haloperidol in Treatment of Schizophrenic Patients - Results of a Double-Blind Study , 1990, Pharmacopsychiatry.
[52] C. M. Rijn,et al. Binding of the cage convulsant, [3H]TBOB, to sites linked to the GABAA receptor complex. , 1990 .
[53] Y. Lecrubier,et al. Treatment of positive and negative symptoms: pharmacologic approaches. , 1990, Modern problems of pharmacopsychiatry.
[54] Philip Seeman,et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine , 1991, Nature.
[55] M. Martres,et al. The Third Dopamine Receptor (D3) as an Autoreceptor , 1991 .
[56] Susan R. George,et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1 , 1991, Nature.
[57] G. Fagg,et al. [3H]CGP 39653: a new N-methyl-D-aspartate antagonist radioligand with low nanomolar affinity in rat brain. , 1991, European journal of pharmacology.
[58] F. Gonon,et al. Presynaptic autoinhibition of the electrically evoked dopamine release studied in the rat olfactory tubercle byin vivo electrochemistry , 1991, Neuroscience.
[59] H. Meltzer,et al. The mechanism of action of novel antipsychotic drugs. , 1991, Schizophrenia bulletin.
[60] S. Snyder,et al. σ Receptors: From Molecule to Man , 1991 .
[61] M. Martres,et al. Localization and function of the D3 dopamine receptor. , 1992, Arzneimittel-Forschung.
[62] M. Martres,et al. The third dopamine receptor (D3) as a novel target for antipsychotics. , 1992, Biochemical pharmacology.
[63] P. Seeman. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[64] S. Bischoff. LIMBIC SELECTIVE NEUROLEPTICS , 1992, Clinical neuropharmacology.
[65] M. Martres,et al. Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. , 1992, European journal of pharmacology.
[66] Meltzer Hy. New Drugs for the Treatment of Schizophrenia , 1993 .
[67] M. Piercey,et al. The dopamine D3 receptor and autoreceptor preferring antagonists (+)-AJ76 and (+)-UH232; a microdialysis study. , 1993, European journal of pharmacology.
[68] K. Lloyd,et al. Characterization of the nipecotic binding to rat brain membranes. , 1993, General pharmacology.
[69] H. Meltzer,et al. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. , 1993, The Journal of pharmacology and experimental therapeutics.
[70] A. Gifford,et al. A pharmacological analysis of the effects of (+)-AJ 76 and (+)-UH 232 at release regulating pre- and postsynaptic receptors , 1993 .
[71] D. Jackson,et al. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. , 1993, Molecular pharmacology.
[72] H. Schoemaker. [3H]7-OH-DPAT labels both dopamine D3 receptors and σ sites in the bovine caudate nucleus , 1993 .
[73] H. Meltzer. New drugs for the treatment of schizophrenia. , 1993, The Psychiatric clinics of North America.
[74] A pharmacological analysis of the effects of (+)-AJ 76 and (+)-UH 232 at release regulating pre- and postsynaptic dopamine receptors. , 1993, European journal of pharmacology.
[75] M. Goldstein,et al. Evidence that striatal synthesis-inhibiting autoreceptors are dopamine D3 receptors. , 1993, European journal of pharmacology.
[76] H. Schoemaker,et al. Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. , 1993, European journal of pharmacology.
[77] Gavin Kilpatrick,et al. Development of a radioligand binding assay for 5‐HT4 receptors in guinea‐pig and rat brain , 1993, British journal of pharmacology.
[78] A. Carlsson,et al. Intracerebral infusion of (+)-AJ76 and (+)-UH232: effects on dopamine release and metabolism in vivo. , 1994, European journal of pharmacology.
[79] M. Martres,et al. Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. , 1994, European journal of pharmacology.
[80] H. Niznik,et al. D1A, D1B, and D1C dopamine receptors from Xenopus laevis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[81] A. Carlsson,et al. Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. , 1994, European journal of pharmacology.
[82] Bernd Saletu,et al. Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine. , 1994 .
[83] S. Z. Langer,et al. Expression of α1-adrenoceptor subtypes in rat tissues : implications for α1-adrenoceptor classification , 1994 .
[84] M. Millan,et al. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. , 1995, The Journal of pharmacology and experimental therapeutics.
[85] H. Schoemaker,et al. Binding of [3H]cirazoline to an imidazoline site in rat brain and kidney membranes. , 1995, European journal of pharmacology.
[86] P. Sokoloff,et al. A functional test identifies dopamine agonists selective for D3 versus D2 receptors. , 1995, Neuroreport.
[87] H. Niznik,et al. The Dopamine D1D Receptor , 1995, The Journal of Biological Chemistry.
[88] D. Wallace,et al. Dopamine D2 and D3 receptors in the rat striatum and nucleus accumbens: Use of 7‐OH‐DPAT and [125I]‐Iodosulpride , 1995, Synapse.
[89] M. Heilig,et al. Dopamine D3 receptor antisense influences dopamine synthesis in rat brain. , 1995, Neuroreport.
[90] M. Millan,et al. Activation of dopamine D3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo. , 1995, European journal of pharmacology.
[91] M. Galloway,et al. Dopamine D3-preferring ligands act at synthesis modulating autoreceptors. , 1995, The Journal of pharmacology and experimental therapeutics.
[92] J. Kehne,et al. The role of 5-HT2A receptors in antipsychotic activity. , 1995, Life sciences.
[93] Y. Lecrubier,et al. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. , 1995, The American journal of psychiatry.
[94] Y. Lecrubier,et al. Treatment of Negative Symptoms in Schizophrenia with Amisulpride , 1995, British Journal of Psychiatry.
[95] M. Galloway,et al. Dopamine autoreceptor reserve in vitro: possible role of dopamine D3 receptors. , 1996, European journal of pharmacology.
[96] D J Sanger,et al. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. , 1997, The Journal of pharmacology and experimental therapeutics.
[97] Discriminative stimulus properties of 8-OH-DPAT : relationship to affinity for 5 HT 1 A receptors , .